크론병 치료 시장 규모, 점유율, 동향 및 성장 분석 보고서(2026-2034년)

The Crohn's Disease Treatment Market size is expected to reach USD 24.54 Billion in 2034 from USD 18.38 Billion (2025) growing at a CAGR of 3.26% during 2026-2034.

The global Crohn's disease treatment market is experiencing steady growth due to the increasing prevalence of inflammatory bowel diseases (IBD) worldwide. Crohn's disease is a chronic condition that causes inflammation in the digestive tract and requires long-term medical management. Growing awareness about gastrointestinal disorders and improved diagnostic techniques are contributing to the rising demand for effective treatment options.

One of the major drivers of this market is the increasing development of advanced biologic therapies and targeted treatment approaches. Pharmaceutical companies are focusing on developing innovative drugs that can reduce inflammation and improve patient quality of life. Additionally, rising healthcare expenditure and better access to specialized healthcare services are supporting the adoption of advanced treatment options.

In the coming years, the Crohn's disease treatment market is expected to witness strong growth as research in immunology and biologic drug development continues to advance. The introduction of novel therapies, including biosimilars and personalized treatment approaches, is likely to improve treatment outcomes. Increasing patient awareness and improved healthcare infrastructure will further contribute to the expansion of this market globally.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Type

• Non-SurgicalA (Anti-Inflammatory, Immune System Suppressors, Antibiotics, Others)
• Surgical

By Route of Administration

• Injectable
• Oral

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

COMPANIES PROFILED

• Takeda Pharmaceutical Company Limited, , AbbVie Inc, Perrigo Company plc, Pfizer Inc, Johnson Johnson Services Inc, Ferring BV, BristolMyers Squibb Company Celgene Corporation, F HoffmannLa Roche Ltd Genentech Inc, UCB SA, Salix Pharmaceuticals, Gilead Sciences Inc
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL CROHN'S DISEASE TREATMENT MARKET: BY TYPE 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Type
• 4.2. Non-Surgical (Anti-Inflammatory, Immune System Suppressors, Antibiotics, Others) Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Surgical Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL CROHN'S DISEASE TREATMENT MARKET: BY ROUTE OF ADMINISTRATION 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Route Of Administration
• 5.2. Injectable Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Oral Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL CROHN'S DISEASE TREATMENT MARKET: BY DISTRIBUTION CHANNEL 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Distribution Channel
• 6.2. Hospital Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Retail Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Online Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL CROHN'S DISEASE TREATMENT MARKET: BY REGION 2022-2034 (USD MN)

• 7.1. Regional Outlook
• 7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.2.1 By Type
  • 7.2.2 By Route Of Administration
  • 7.2.3 By Distribution Channel
  • 7.2.4 United States
  • 7.2.5 Canada
  • 7.2.6 Mexico
• 7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.3.1 By Type
  • 7.3.2 By Route Of Administration
  • 7.3.3 By Distribution Channel
  • 7.3.4 United Kingdom
  • 7.3.5 France
  • 7.3.6 Germany
  • 7.3.7 Italy
  • 7.3.8 Russia
  • 7.3.9 Rest Of Europe
• 7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.4.1 By Type
  • 7.4.2 By Route Of Administration
  • 7.4.3 By Distribution Channel
  • 7.4.4 India
  • 7.4.5 Japan
  • 7.4.6 South Korea
  • 7.4.7 Australia
  • 7.4.8 South East Asia
  • 7.4.9 Rest Of Asia Pacific
• 7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.5.1 By Type
  • 7.5.2 By Route Of Administration
  • 7.5.3 By Distribution Channel
  • 7.5.4 Brazil
  • 7.5.5 Argentina
  • 7.5.6 Peru
  • 7.5.7 Chile
  • 7.5.8 Rest of Latin America
• 7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.6.1 By Type
  • 7.6.2 By Route Of Administration
  • 7.6.3 By Distribution Channel
  • 7.6.4 Saudi Arabia
  • 7.6.5 UAE
  • 7.6.6 Israel
  • 7.6.7 South Africa
  • 7.6.8 Rest of the Middle East And Africa

Chapter 8. COMPETITIVE LANDSCAPE

• 8.1. Recent Developments
• 8.2. Company Categorization
• 8.3. Supply Chain & Channel Partners (based on availability)
• 8.4. Market Share & Positioning Analysis (based on availability)
• 8.5. Vendor Landscape (based on availability)
• 8.6. Strategy Mapping

Chapter 9. COMPANY PROFILES OF GLOBAL CROHN'S DISEASE TREATMENT INDUSTRY

• 9.1. Top Companies Market Share Analysis
• 9.2. Company Profiles
  • 9.2.1 AbbVie Inc
  • 9.2.2 Perrigo Company Plc
  • 9.2.3 Pfizer Inc
  • 9.2.4 Johnson & Johnson Services Inc
  • 9.2.5 Ferring B.V
  • 9.2.6 Bristol-Myers Squibb Company (Celgene Corporation)
  • 9.2.7 F. Hoffmann-La Roche Ltd (Genentech Inc.)
  • 9.2.8 UCB S.A
  • 9.2.9 Salix Pharmaceuticals
  • 9.2.10 Gilead Sciences Inc